Both groups | Standard care group | Intervention group | |||||||
All patients | <5 ng/L | 5–14 ng/L | >14 ng/L | All patients | <5 ng/L | 5–14 ng/L | >14 ng/L | ||
(n=10 315) | (n=6642) | (n=2188) | (n=1885) | (n=2569) | (n=3673) | (n=945) | (n=1380) | (n=1348) | |
Age (mean) | 63.57 (16.4) | 63.77 (16.3) | 50.31 (12.6) | 65.25 (12.8) | 74.14 (13.1) | 63.20 (16.4) | 48.04 (12.1) | 63.02 (13.4) | 74.01 (13.1) |
Sex (male), n (%) | 5571 (54.0%) | 3628 (54.6%) | 994 (45.4%) | 1121 (59.5%) | 1513 (58.9%) | 1943 (52.9%) | 368 (38.9%) | 804 (58.3%) | 771 (57.2%) |
Medical history | |||||||||
Myocardial infarction, n (%) | 660 (6.4%) | 507 (7.6%) | 70 (3.2%) | 151 (8.0%) | 286 (11.1%) | 153 (4.2%) | 12 (1.3%) | 64 (4.6%) | 77 (5.7%) |
Diabetes mellitus, n (%) | 1823 (17.7%) | 1177 (17.7%) | 154 (7.0%) | 345 (18.3%) | 678 (26.4%) | 646 (17.6%) | 70 (7.4%) | 218 (15.8%) | 358 (26.6%) |
Heart failure, n (%) | 432 (4.2%) | 315 (4.7%) | 9 (0.4%) | 36 (1.9%) | 270 (10.5%) | 117 (3.2%) | 2 (0.2%) | 16 (1.2%) | 99 (7.3%) |
Medication at presentation | |||||||||
Antiplatelets, n (%) | 3387 (32.8%) | 2311 (34.8%) | 346 (15.8%) | 718 (38.1%) | 1247 (48.5%) | 1076 (29.3%) | 86 (9.1%) | 439 (31.8%) | 551 (40.9%) |
ACE inhibitor or ARB, n (%) | 3192 (30.9%) | 2095 (31.5%) | 376 (17.2%) | 692 (36.7%) | 1027 (40.0%) | 1097 (29.9%) | 127 (13.4%) | 484 (35.1%) | 486 (36.1%) |
Beta-blocker, n (%) | 2723 (26.4%) | 1810 (27.3%) | 330 (15.1%) | 560 (29.7%) | 920 (35.8%) | 913 (24.9%) | 124 (13.1%) | 355 (25.7%) | 434 (32.2%) |
Lipid-lowering therapy, n (%) | 3931 (38.1%) | 2623 (39.5%) | 442 (20.2%) | 854 (45.3%) | 1327 (51.7%) | 1308 (35.6%) | 138 (14.6%) | 549 (39.8%) | 621 (46.1%) |
Diuretic therapy, n (%) | 1504 (14.6%) | 1018 (15.3%) | 59 (2.7%) | 181 (9.6%) | 778 (30.3%) | 486 (13.2%) | 22 (2.3%) | 111 (8.0%) | 353 (26.2%) |
Laboratory results | |||||||||
Creatinine (µmol/L) (SD) | 93 (53) | 94 (53) | 75 (15) | 85 (22) | 116 (76) | 92 (55) | 73 (18) | 83 (25) | 113 (81) |
Efficacy | |||||||||
Duration of stay (minutes) | 469 (220–2148) | 534 (220–2279) | 236 (180–484) | 421 (215–1214) | 2259 (665–6054) | 390 (218–1190) | 219 (170–329) | 311 (215–838) | 2567 (679–6191) |
Four-hour discharge (yes)* | 3431 (33.5%) | 2150 (32.4%) | 1149 (52.5%) | 661 (35.1%) | 340 (13.2%) | 1281 (34.9%) | 604 (63.9%) | 512 (37.1%) | 165 (12.2%) |
All-cause death (%) | |||||||||
At 1 year | 1102 (10.7%) | 721 (10.9%) | 17 (0.8%) | 73 (3.9%) | 631 (24.6%) | 381 (10.4%) | 4 (0.4%) | 48 (3.5%) | 329 (24.4%) |
At 30 days | 386 (3.7%) | 245 (3.7%) | 1 (0.0%) | 14 (0.7%) | 230 (9.0%) | 141 (3.8%) | 1 (0.1%) | 12 (0.9%) | 128 (9.5%) |
Cardiovascular death | |||||||||
At 1 year | 568 (5.5%) | 364 (5.5%) | 4 (0.2%) | 20 (1.1%) | 340 (13.3%) | 204 (5.6%) | 1 (0.1%) | 17 (1.2%) | 186 (13.8%) |
At 30 days | 221 (2.1%) | 139 (2.1%) | 1 (0.0%) | 4 (0.2%) | 134 (5.2%) | 82 (2.2%) | 1 (0.1%) | 8 (0.6%) | 73 (5.4%) |
Continuous variables are presented as mean (SD) or median (IQR). Categorical variables are presented as n (%).
*Sixty-eight patients with missing data (45 patients from standard group and 23 patients from intervention group).
ARB, angiotensin receptor blocker.